PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arch Gen Psychiatry. Author manuscript; available in PMC Sep 20, 2012.
Published in final edited form as:
PMCID: PMC3447632
NIHMSID: NIHMS377782
Neural Correlates of Affect Processing and Aggression in Methamphetamine Dependence
Doris E. Payer, Ph.D.,1 Matthew D. Lieberman, Ph.D.,1,2 and Edythe D. London, Ph.D.1,3,4
1UCLA Department of Psychiatry & Biobehavioral Sciences
2UCLA Department of Psychology
3UCLA David Geffen School of Medicine, Department of Molecular & Medical Pharmacology
4UCLA Brain Research Institute
Correspondence: Edythe D. London, PhD, UCLA Semel Institute, 740 Westwood Plaza, Room C8-528, Los Angeles, CA 90095 (elondon/at/mednet.ucla.edu).
Context
Methamphetamine abuse is associated with high rates of aggression, but few studies have addressed the contributing neurobiological factors.
Objective
To quantify aggression, investigate function of the amygdala and prefrontal cortex, and assess relationships between brain function and behavior in methamphetamine-dependent individuals.
Design
In a case-control study, aggression and brain activation were compared between methamphetamine-dependent and control participants.
Setting
Participants were recruited from the general community to an academic research center.
Participants
Thirty-nine methamphetamine-dependent volunteers (16 women) who were abstinent for 7 to 10 days and 37 drug-free control volunteers (18 women) participated in the study; subsets completed self-report and behavioral measures. Functional magnetic resonance imaging (fMRI) was performed on 25 methamphetamine-dependent and 23 control participants.
Main outcome measures
We measured self-reported and perpetrated aggression, and self-reported alexithymia. Brain activation was assessed using fMRI during visual processing of facial affect (affect matching), and symbolic processing (affect labeling), the latter representing an incidental form of emotion regulation.
Results
Methamphetamine-dependent participants self-reported more aggression and alexithymia than control participants and escalated perpetrated aggression more following provocation. Alexithymia scores correlated with measures of aggression. During affect matching, fMRI showed no differences between groups in amygdala activation, but found lower activation in methamphetamine-dependent than control participants in bilateral ventral inferior frontal gyrus. During affect labeling, participants recruited dorsal inferior frontal gyrus and exhibited decreased amygdala activity, consistent with successful emotion regulation; there was no group difference in this effect. The magnitude of decrease in amygdala activity during affect labeling correlated inversely with self-reported aggression in control participants, and perpetrated aggression in all participants. Ventral inferior frontal gyrus activation correlated inversely with alexithymia in control participants.
Conclusions
Contrary to the hypotheses, methamphetamine-dependent individuals may successfully regulate emotions through incidental means (affect labeling). Instead, low ventral inferior frontal gyrus activity may contribute to heightened aggression by limiting emotional insight.
Methamphetamine (MA) abuse is associated with a propensity for irritability, hostility, and aggression, resulting in high rates of interpersonal violence, emergency room/trauma center visits, assault and weapons charges1-9, and ultimately public health and safety burdens10, 11. Despite the frequent co-occurrence of aggression with MA abuse12-14, however, the nature of their relationship remains under debate15-17. Few laboratory studies have evaluated socio-emotional function in MA-abusing individuals18, 19, and only one has directly assessed aggression20. The aim of the present study, therefore, was to delineate possible relationships between brain function, emotion processing, and aggression in individuals who abuse MA.
Aggression (particularly impulsive aggression) is defined as any action toward another person that is elicited by provocation, driven by anger, and intended to cause harm. Its generation is conceptualized by the General Aggression Model21, in which internal states are translated into either impulsive aggression or thoughtful action, depending on the success of appraisal and decision processes. These processes require introspection (i.e., appraisal and evaluation of one’s internal state) but they are only deployed if sufficient cognitive resources are available. As such, both cognitive capacity and emotional insight are necessary to produce a thoughtful outcome, while failure of either faculty can result in aggression.
Both faculties have been investigated in MA-abusing individuals. Studies of cognitive capacity22, 23 have suggested deficits in attentional control24, response inhibition25, 26, cognitive flexibility27, and decision-making28-30. Similarly, studies of emotional insight31, 32 have described poor self-awareness33 and difficulty with facial affect recognition and theory of mind19. Disturbances in either capacity described by the General Aggression Model could therefore contribute to MA-related aggression, but these links have not been tested directly.
Neurobiologically, aggression is associated with emotion processing circuitry, particularly the amygdala and prefrontal cortex (PFC)34. Whereas the amygdala mediates rapid, automatic responses to social stimuli35, 36, especially emotional facial expressions37, 38, PFC mediates the more deliberative aspects of emotion processing39, with its ventral sectors implicated in semantic processing and integration of emotional information40-42, as well as response selection and behavior control43. The PFC can modulate amygdala activity through direct and indirect connections44-46, and aggressive behavior relies on the integrity of this connectivity. Low PFC activity, high amygdala activity, and disruption of their connections have been linked to aggressive behavior in violent and psychiatric populations47-53, and healthy individuals performing emotion regulation tasks, including restraint from aggression54, exhibit PFC activation, reduced amygdala activity55-61, and lowered markers of physiological arousal and subjective distress62-64. These studies have consistently demonstrated involvement of the inferior frontal gyrus (IFG), often on the right side,55, 65, 66 which contributes to inhibitory control67.
Individuals who abuse methamphetamine show abnormalities in this circuitry, suggesting a link between neurobiological deficits and their propensity for aggression. In PFC (particularly IFG68), numerous structural, neurochemical, and metabolic differences have been identified69, 70, and functional magmetic resonance imaging (fMRI) has uncovered deficits in PFC activation during cognitive27, 29, 71, 72 and socio-emotional tasks18, 73. Examination of subcortical regions has also uncovered MA-related neurochemical and metabolic abnormalities in the amygdala20, 74, 75. These neurobiological differences have been linked to moods, psychiatric states, and personality traits that can influence aggression70, 74-78, and in one study, related to psychiatric states, and personality traits that can influence aggression70, 74-78, and in one case related to aggression itself20. However, no study has directly linked functional differences to emotion processing and aggression.
To address this issue, we previously conducted a fMRI study investigating neural responses to emotional facial expressions in MA-dependent individuals18. Surprisingly, the study found no difference between MA dependent and Control participants in amygdala response but revealed activation differences in the right IFG. Because one of the roles ascribed to the right IFG is inhibitory control79, including control over emotional responses80, we reasoned that the IFG finding may relate to emotion dysregulation in the MA group. However, because the task did not assess emotion regulation directly, it was not possible to test this hypothesis. The study presented here therefore extended the task to include such a condition.
The added task condition (affect labeling) involves verbal labeling of emotional facial expressions, which, unlike the previously used visual matching condition (affect matching), requires symbolic representation of affect. In healthy individuals, affect labeling produces neural activation patterns that are consistent with emotion regulation (i.e., increased right IFG and lowered amygdala activity55-57), and is accompanied by decreased markers of negative emotion57, 81. Putting feelings into words, therefore incidentally recruits PFC resources whose activity can influence the amygdala, thereby regulating those feelings82.
This study used fMRI to investigate the integrity of the PFC-amygdala circuit in MA dependent and Control participants and used self-report and behavioral measures to relate brain function to aggression and associated traits. Specific objectives of the study were 1) to quantify and compare aggression in MA and Control participants, (2) determine whether the previously observed difference in right IFG activation18 reflects a deficit in emotion regulation, and (3) investigate how these activation patterns relate to aggression.
Participants and Study Procedure
All procedures were approved by the UCLA Office for the Protection of Research Subjects. Individuals who used MA but were not seeking treatment (MA group) and healthy control individuals (Control group) between the ages of 18 and 55 years were recruited using radio, Internet, and newspaper advertisements. Following an explanation of the study, participants gave written informed consent and were screened for eligibility using questionnaires, psychiatric diagnostic interviewing (Structured Clinical Interview for DSM-IV Axis 1 Disorders83), and a medical examination. Participants in the MA group were required to meet DSM-IV criteria for current MA dependence, and to demonstrate recent MA use by providing a positive urine sample. Exclusion criteria for all participants were any current Axis I diagnosis other than MA dependence or substance-induced mood or anxiety disorder in the MA group or nicotine abuse/dependence in both groups; use of psychotropic medications or substances, except some marijuana or alcohol (not qualifying for abuse or dependence); central nervous system, cardiovascular, pulmonary, or systemic disease; human immunodeficiency virus, severe hepatic impairment, hematocrit lower than 32, prostatic hypertrophy, or chronic inflammation; pregnancy; lack of English fluency; and MRI contraindications.
Eligible MA participants were admitted to the UCLA General Clinical Research Center and participated on a residential basis for 15 to 31 days. They were required to abstain from MA for the duration of the study, verified by urine screening, and no testing occurred in the first 4 days to allow residual MA to clear. Measures presented here were collected over the first 15 days, with the order slightly varied for each participant. Control participants visited the laboratory only on test days and were required to provide urine samples on each test day that tested negative for illicit substances. Upon completion of the study, participants were compensated with cash, gift certificates, and vouchers.
A total of 76 individuals (39 MA-dependent participants, 37 Control) participated in the study. Owing to subject attrition, late addition of measures to the study protocol, and inconsistencies in data collection, not all participants completed all measures. In addition, MRI runs were discarded for excessive head movement, problems acquiring behavioral data, chance performance on the task, claustrophobic reaction, or missing structural data. Of the participants with acceptable fMRI data, 21 (11 MA-dependent participants, 10 Controls) had participated in a previously described study18, while 48 (25 MA-dependent participants, 23 Controls) had performed an updated version of the task (described below).
Measures
Task Paired with fMRI
The Affect Matching/Labeling Task55, 56 is a visual match-to-sample task using face stimuli84 and is designed to elicit characteristic PFC and amygdala activation patterns during each of three conditions: Affect Match, Affect Label, and Shape Match (Figure 1A).
Figure 1
Figure 1
Sample stimuli from the Affect Matching/Labeling Task and Competitive Reaction-Time Task (CRT)
Out-of-Scanner Measures
Competitive Reaction-Time Task (CRT)
The Competitive Reaction Time Task (CRT85) is a measure of perpetrated aggression, operationalized as the amount of aversive noise to which a participant is willing to subject another person. It captures one of the hallmark features of aggression: delivery of a noxious stimulus to a victim with the intent and expectation of harming the victim86. External, convergent, discriminant, and construct validity of the task have been established in previous studies86-88.
In this task (Figure 1B), participants believed they were competing against another person in a reaction time game (pressing a button faster than their opponent following a “go” cue) and that the loser of each trial would be subjected to a noise blast selected by the winner of the trial. In reality, opponent responses were computer controlled. Noise settings selected by the participant for delivery to the opponent on each trial were the outcome measure. Participants were debriefed immediately following completion of the task.
Aggression Questionnaire (AQ)89
For this 34-item paper-and-pencil questionnaire, participants indicated how much each item reflected their behavior on a 5-point scale.
State Trait Anger Expression Inventory (STAXI)90
For this 34-item paper-and-pencil questionnaire, 88 participants indicated how much each item reflected their behavior on a 5-point scale.
Toronto Alexithymia Scale (TAS)91
For the 20-item, paper-and-pencil Toronto Alexithymia Scale (TAS),90 participants rated their agreement with each item on a 5-point scale, yielding 3 measures: difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking.
MA Abstinence Measures
Methamphetamine Withdrawal Questionnaire (MAWQ)
This 30-item, rater-scored questionnaire, described in detail elsewhere,91 is an adaptation of the Amphetamine Withdrawal Questionnaire.92 Participants in the MA group indicated the severity of functional, emotional, and physical withdrawal symptoms on a 4-point scale.
Visual Analog Scale for Craving (VAS)
Participants in the MA group completed this measure daily, indicating current levels of MA craving on a 15-cm line marked from 0 to 100 in 10-point increments.
Apparatus
Functional MRI was performed on a 3.0 Tesla Siemens Allegra (Erlangen, Germany) using a single-channel head coil. Functional images were acquired using a standard T2*-weighted gradient-echo echo-planar imaging pulse sequence to collect blood oxygen level-dependent signal. Acquisition parameters were time to repetition, 2500 milliseconds; echo time, 28 milliseconds; flip angle, 80°; and matrix, 64 × 64. Each volume consisted of 36 interleaved slices, parallel to the anterior commissure-posterior commissure line, with slice thickness of 2.5 mm and a 25% distance factor. Each of 2 functional runs resulted in 210 volumes. T2-weighted and high-resolution T1-weighted (magnetization-prepared rapid-acquisition gradient-echo) structural scans were also acquired.
Stimulus displays for the Affect Matching/Labeling task were generated using MacStim software93 on an Apple MacBook computer (Cupertino, California) and presented through magnet-compatible video goggles.94 Responses were registered using a magnet-compatible button box.94 The CRT was performed using the HyperCard version of the program on an Apple MacBook computer, with noise blasts delivered through TDK headphones (Uniondale, New York).
Data Analysis
Imaging Data
Pre-processing
Functional MRI data were processed using SPM5.95 To correct for head motion (within 3-mm translation or 5° rotation; movement beyond these parameters was exclusionary), functional images were spatially realigned to the mean image of the time series, using a least squares approach and 6-parameter rigid body spatial transformation. Images were then coregistered to individual structural templates to allow for localization of activation and subsequent spatial normalization.
Amygdala region-of-interest (ROI) analysis
Amygdala regions of interest (ROIs) were drawn on individual magnetization-prepared rapid-acquisition gradient-echo images using FSL FIRST software.96 Functional scans were smoothed with a 5-mm Gaussian kernel and masked with the ROIs. Using the MarsBaR toolbox,97 a general linear model was applied at each voxel within the ROIs, containing a regressor for each condition of the task (affect match, shape match, and affect label for the subset completing this condition), and fixation as an implicit baseline. Condition blocks were modeled as boxcar functions, convolved with a hemodynamic response function provided by SPM. After fitting the general linear model, parameter estimates were averaged across all voxels in the ROI, and the resulting values exported for further analysis.
Whole-brain analysis
For individual whole-brain analyses, functional images were smoothed with an 8-mm Gaussian kernel, and the general linear model described above was applied at each voxel across the brain. After fitting the model for each participant, the resulting maps of parameter estimates were spatially normalized to a standard template provided by SPM using a 12-parameter affine transformation and passed to a group-level random-effects analysis. The group-level model combined the previously described18 and added sample, and included sample, group, and sex as factors and age and education as covariates of no interest to account for any potentially confounding effects.
Psychophysiological interaction (PPI) analysis
Effective connectivity between IFG and the amygdala was assessed using the psychophysiological interaction function in SPM5. Psychophysiological interaction analysis uses a multiple regression approach to isolate regions showing a differential relationship with a target region depending on psychological context and can be interpreted as the context-specific influence one brain region exerts over another.98-99 In the present study, individual FIRST-generated amygdala ROIs served as the target, conditions of the affect matching/labeling task as the manipulated context, and IFG as a potential source region for connectivity.
For each participant, regressors that modeled amygdala activity, task conditions, and the amygdala × condition interaction were entered into whole-brain multiple regression analysis. Given our a priori hypotheses,55-56 analyses were restricted to IFG using the PickAtlas toolbox.100 After estimating the model for each participant, a linear contrast was specified for a greater inverse relationship with the amygdala during the affect label than affect match condition. The resulting statistical maps were spatially normalized to the standard SPM template and passed to a group-level random effects analysis, with group and sex as factors and age and education as covariates of no interest.
All whole-brain group analyses were assessed at a statistical threshold of P < .005 with a cluster criterion of at least 30 contiguous voxels, offering a good balance between type I and type II error.101
Brain Structure
To account for potentially confounding structural differences,68 we examined volumetric information from individual FIRST- generated amygdala ROIs and IFG gray matter volume using voxel-based morphometry.102 For the voxel-based morphometry analysis, individual magnetization-prepared rapid-acquisition gradient-echo images were manually aligned to the anterior commissure-posterior commissure line, segmented into 3 tissue types, spatially normalized to a standard template, modulated to adjust for nonlinear warping, and smoothed using a 12-mm full-width at half-maximum Gaussian kernel. Signal intensity values, representing an index of regional gray matter volume, were then extracted from voxels of interest for further analysis.
Behavioral and ROI Data
The remaining data were analyzed in SPSS 16.0 (SPSS Inc, Chicago, Illinois), using analysis of variance (ANOVA) and regression models. Because we were unable to match the groups for age and education, and aggression and associated neurocircuitry vary with age and sex,103 demographic variables were entered into all analyses as covariates of no interest.
Participant Characteristics
Demographic measures are detailed in the Supplementary Table 1. The MA and control groups did not differ in sex composition but, on average, MA-dependent participants were older than controls and had completed fewer years of education. Almost all MA-dependent participants but only about half of the controls smoked cigarettes; however, the number of cigarettes per day did not differ between groups among those who smoked. Current alcohol use was low across participants and did not differ between groups. Methamphetamine use characteristics indicated moderately heavy use in the present sample (Table 1). Withdrawal symptoms and cravings tended to decrease between intake and test days but not all differences reached statistical significance (Table 2). Neither MA use nor abstinence measures correlated with outcome measures.
Table 1
Table 1
Demographic and Methamphetamine Use Characteristics of Participantsa
Table 2
Table 2
Methamphetamine Abstinence Measures by Subsample
Aggression and Trait Characteristics
To compare self-reported aggression between groups, we performed univariate ANOVAs on Aggression Questionnaire, STAXI trait anger, and STAXI anger expression scores, with group as a between-subjects factor and demographic variables as covariates of no interest. All tests showed significant differences between groups, with higher scores in MA-dependent than control participants (Table 3).
Table 3
Table 3
Outcome Measures by Subsamplea
To compare perpetrated aggression between groups, we examined CRT performance. Noise intensity and duration settings correlated during all blocks (all r > 0.66; all P < .001) and were summed to form a composite score. Repeated-measures ANOVA of these scores, with group as a between-subjects factor and block as a within-subjects factor, showed a significant block × group interaction. Follow-up tests revealed higher scores in MA-dependent than control participants during block 4 (peak provocation) but no significant group differences for trial 1, block 2, or block 3 (Figure 2).
Figure 2
Figure 2
Perpetrated aggression across CRT blocks
To evaluate group differences in alexithymia, we performed univariate ANOVAs on TAS subscales, with group as a between-subjects factor and demographic variables as covariates. The MA-dependent participants reported more difficulty identifying feelings than controls but no differences in describing feelings or externally oriented thinking (Table 3). Across control participants, TAS difficulty identifying feelings correlated with STAXI trait anger (r = 0.57; P = .009) and anger expression (r = 0.47; P = .04). Across MA-dependent participants, TAS total scores correlated with STAXI anger expression (r = 0.42; P = .04).
Functional MRI
Affect Matching
Across all participants, the affect match vs shape match contrast showed widespread activation consistent with the neural system for face processing,103-104 including in the bilateral amygdala and IFG (Table 4). Within these regions, t tests comparing groups revealed lower activation in MA-dependent than control participants in bilateral ventral IFG, predominantly on the right (Figure 3A; Table 4). No regions showed greater activation in MA-dependent than control participants.
Table 4
Table 4
Functional MRI Clusters During Affect Matching/Labeling Task Performancea
Figure 3
Figure 3
IFG and amygdala activation patterns during the Affect Matching/Labeling Task
To account for potential volumetric differences between groups,68 we examined individual gray matter concentration in these ventral IFG clusters using voxel-based morphometry. An ANOVA testing voxel-based morphometry values for group differences showed a trend toward lower gray matter concentration in the MA group (F1,54 = 2.86; P = .10) (in addition to effects of age and sex). To test whether local gray matter concentration influenced task-related ventral IFG activation, we entered gray matter concentration as a covariate into an ANOVA, comparing activation between groups. Activation values (average parameter estimates in ventral IFG clusters) correlated between left and right clusters (r = 0.57; P < .001) and were combined by calculating a cluster-weighted average. The ANOVA showed no effect of gray matter concentration on these values, while the group difference remained (Table 3).
Finally, we investigated amygdala activation for differences between groups. Volume of amygdala ROIs differed by sex but not group (F1,64 = 1.21; P = .28). Left and right amygdala activation values (average parameter estimates across ROI voxels) correlated with one another (r = 0.68; P < .001) and were combined by calculating their average. An ANOVA of these values, with group as a factor and ROI volume as a covariate, revealed no effect of volume or group difference in activation (Tables 2 and and33).
Affect Labeling
To test the hypothesis that, owing to IFG dysfunction, MA-dependent participants would fail to lower amygdala activity during affect labeling, we performed a repeated-measures ANOVA on amygdala activation values, with group as a between-subjects factor and condition (affect match, affect label, shape match) as a within-subjects factor. Activation values from left and right amygdala ROIs correlated during all task conditions (all r > 0.61; all P < .001), and were combined by calculating the average. The ANOVA showed a significant effect of condition, and follow-up tests revealed that, as predicted, amygdala activity during the affect label condition was lower than during the affect match condition. Activation during the shape match condition was lower than during both conditions involving faces. Contrary to prediction, however, we found no group difference or group × condition interaction (Figure 3B).
To identify brain regions associated with this reduction in amygdala activation, we tested voxels across IFG for a greater inverse relationship with amygdala activity (i.e., greater functional connectivity) during affect label than affect match using psychophysiological interaction analysis. Dorsal IFG showed the expected pattern of connectivity, predominantly on the right (Figure 3C, Table 4). The clusters did not overlap with the ventral IFG clusters that showed a group difference during affect matching. Within the dorsal IFG clusters, no voxels differed between MA-dependent and control participants, suggesting successful IFG recruitment and subsequent amygdala regulation in both groups.
Behavioral Correlates of Decreased Amygdala Activity
Individual decreases in amygdala activity were calculated as the difference in activation between affect match and affect label conditions. To determine the functional significance of this decrease, values were entered as independent variables into linear regression models, with aggression scores as the outcome variables and demographic measures as covariates of no interest. Self-reported aggression scores were intercorrelated (all r > 0.47; all P < .01) and were combined into a composite score by calculating their average.
The model examining these scores showed a relationship between decreased amygdala activity and self-reported aggression in control but not MA-dependent participants (Figure 4A). However, MA-dependent participants showed a relationship between decreased amygdala activity and CRT scores (Figure 4B). Control participants showed a similar relationship (Figure 4B) that did not reach statistical significance, possibly because of low statistical power owing to the small subsample. When the 2 groups were combined to increase statistical power, decreased amygdala activity, controlling for group, showed a significant inverse relationship with CRT performance (r = −0.45; P = .03).
Figure 4
Figure 4
Relationships between decreased amygdala activity and aggression
Behavioral Correlates of ventral IFG Activity
Because low ventral IFG activity in the MA group (Figure 3A) did not signify emotion dysregulation, we investigated its functional significance using linear regression. Ventral IFG activation (cluster-weighted average of left and right clusters) was entered as the independent variable, with behavioral measures as outcomes and demographic measures as covariates. In controls, ventral IFG activation did not directly relate to aggression but showed a significant inverse relationship with scores on the difficulty identifying feelings subscale of the TAS (Figure 5), suggesting that ventral IFG contributes to emotional insight. In MA-dependent participants, ventral IFG activation did not relate to TAS scores, suggesting a decoupling owing to their functional deficit in this region.
Figure 5
Figure 5
Relationship between ventral IFG activation and emotional insight
The results are consistent with the view that emotional insight, in addition to emotion regulation, contributes to aggression,21 and that this capacity involves the ventral IFG.105-107 Low ventral IFG activity and associated alexithymia in MA-dependent individuals may therefore precipitate aggression despite successful emotion regulation. Because results were found in early abstinence and did not relate to MA use history or withdrawal, they also suggest that at least some proportion of MA-related aggression is mediated by personality characteristics rather than acute intoxication, withdrawal, or MA use history.
In this study, MA-dependent participants self-reported higher aggression than controls, replicating previous findings20 and confirming descriptions from community samples.1-9 The MA-dependent participants also perpetrated more aggression on the CRT, where, despite similar initial behavior to controls, they escalated aggression more steeply following provocation. These results provide the first laboratory description of MA-related aggression patterns and suggest that aggression occurs as an increasingly disproportionate response to interpersonal interaction, rather than a preemptive attack.
According to the General Aggression Model,21 failure of either emotion regulation or emotional insight can account for such a pattern. Despite our hypotheses’ focus on emotion regulation, however, we found no deficit in this capacity in MA-dependent participants, as affect labeling resulted in dorsal IFG recruitment and lowered amygdala activity across participants. These activation patterns related to self-reported aggression in controls and perpetrated aggression in all participants, suggesting that they represent a neural signature for successful emotion regulation55, 57 and that this capacity is relevant to the restraint of aggression in both groups.
Instead, poor emotional insight may underlie MA-related aggression. The General Aggression Model states that even in the presence of sufficient cognitive capacity (i.e., emotion regulation), behavior can be aggressive if assessment of internal states is unsuccessful. Alexithymia scores in the MA sample support this view, showing greater difficulty identifying feelings, which, in turn, related to self-reported aggression. This finding is consistent with evidence of impaired introspection and social comprehension in drug addiction31-32 and evidence that MA-related hostility results in part from misinterpretation of the world as a hostile and threatening place.108
Importantly, our imaging data suggest that emotional insight relies on the ventral IFG, a region showing dysfunction in MA-dependent participants. During facial affect matching, MA-dependent participants showed low activity in bilateral ventral IFG (not overlapping with the dorsal IFG region implicated in amygdala regulation), while amygdala activation did not differ between groups. These results replicate and extend our previous findings18 and suggest that, while amygdala-dependent automatic reactions to socioemotional cues are comparable with those of healthy individuals, IFG-dependent deliberative processing is compromised. Ventral IFG is implicated in the recognition, representation, and comprehension of emotionally salient information, including the mental and emotional states of oneself and others,40-42, 109 and neurocognitive models suggest that its activity can influence behavioral outcomes by modulating hypothalamic “fight-or-flight” responses following comprehension of socioemotional cues.110-111 The inverse correlation between ventral IFG activity and alexithymia observed in the controls is consistent with this evidence and suggests that low ventral IFG activity (as exhibited by MA-dependent participants) reflects a limited capacity to identify feelings. In line with a previously described relationship between ventral IFG function and harm avoidance/fear in MA-dependent individuals,76 this deficit could diminish the motivation to temper maladaptive interpersonal behavior, thus escalating aggression.
Beyond increasing the likelihood of aggression, the same deficit could also contribute to the unreliable self-reporting observed among MA-dependent participants. The finding that in the MA group, decreased amygdala activity related to perpetrated aggression but not self-report of this aggression suggests that, owing to limited insight, objective tasks characterize their behavior more reliably than subjective self-report.
Together, the data are consistent with theoretical21 and neurocognitive111 models of aggression and suggest that a deficit in the evaluation of internal states rather than insufficient cognitive capacity precipitates MA-related aggression. Amygdala activation during affect matching suggests appropriate immediate responses, and successful amygdala regulation by dorsal IFG during affect labeling suggests sufficient cognitive capacity; however, low ventral IFG activation and associated alexithymia suggest limited evaluation of internal states, thus favoring aggressive outcomes.
Several limitations of the study should be noted. First, we were unable to match MA-dependent and control participants for age, education, psychiatric history, and smoking status, potentially confounding group differences. Although we included demographic covariates in analyses and performed follow-up tests, we recognize that MA-dependent and control participants likely differ in ways other than MA exposure and that these factors need to be distinguished in future studies. Second, MA-related abnormalities in neurovascular coupling or hemodynamic response could have influenced fMRI results. To minimize such effects, the study used a blocked design but this decreased temporal resolution. The surprising lack of a group difference in amygdala activity or regulation could therefore reflect the low temporal resolution of the design (or the low spatial resolution of fMRI) rather than true equivalence in function. Further, amygdala and ventral PFC are susceptible to signal dropout, potentially obscuring the data. Third, decreased amygdala activation between affect match and label conditions could have resulted from factors other than inhibitory control processes such as differences in stimulus parameters or attention. However, Lieberman et al55 have shown that amygdala activity decreases with affect labeling but not perceptual and attentional control conditions, and other studies57, 80 have shown associated decreases in subjective measures of emotion, making incidental emotion regulation a plausible interpretation. Finally, although our data suggest that alexithymia is a crucial contributor to MA-related aggression, the possibility that additional trait characteristics (eg, impulsivity, volatile temper, sensation-seeking) mediate this relationship cannot be excluded.
These limitations notwithstanding, the study adds important neurobiological components to the examination of aggression in MA dependence. The findings suggest that emotion regulation, at least when elicited incidentally, can be successful in MA-dependent individuals but that dysfunction of ventral IFG contributes to heightened aggression by limiting emotional insight. In the continued pursuit of intervention strategies focused on stress-related relapse prevention and improved personal and social function, future studies may therefore benefit from taking these socioemotional considerations into account.
Supplementary Material
Supplementary Table
ACKNOWLEDGMENTS
Funding/Support: This study was supported by National Institutes of Health grants R01 DA020726, R01 DA015179, P20 DA022539 (Dr London) and R01 MH084116 (Dr Lieberman); individual fellowship F31 DA025422 (Dr Payer); Guggenheim Grant 20070111 (Dr Lieberman); institutional training grants T90 DA022768, T32 DA024635, and M01 RR00865 (UCLA General Clinical Research Center); endowments from the Katherine K. and Thomas P. Pike Chair in Addiction Studies; and the Marjorie Green Family Trust (Dr London).
Additional Contributions: The authors thank Todd Zorick, MD, PhD, for clinical oversight of the study; Catherine Sugar, PhD, for statistical advice; Sarah Wilson, MA, for coordination of the study; Angelica Morales for helpful comments and contribution of voxel-based morphometry data; Kristina Mouzakis and Greg Shipman for database support; and Christine Baker, Clayton Clement, Natalie DeShetler, Bahar Ebrat, Lisa Giragosian, Tom Hanson, MA, Lindsay King, Nathasha Moallem, Brittany Sumerel, and Mary Walker Susselman, CNMT, RT(N)(MR), for participant recruitment, screening, and retention. We also thank 3 anonymous reviewers for their helpful comments.
Footnotes
Author Contributions: Dr London takes responsibility for the integrity of the data and the accuracy of analyses. Drs London and Payer had full access to the data in the study.
Financial Disclosure: None reported.
Disclaimer: The funding sources had no role in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript.
Previous Presentations: This study was presented in part at the annual meetings of the Organization for Human Brain Mapping; June 18-23, 2009; San Francisco, California; and the Society for Neuroscience; October 17-21, Chicago, Illinois.
Additional Information: A subset of the sample described in this article was used in a previous publication.18
1. Logan BK, Fligner CL, Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci. 1998 Jan;43(1):28–34. PubMed. [PubMed]
2. Maxwell JC. Emerging research on methamphetamine. Curr Opin Psychiatry. 2005 May;18(3):235–242. PubMed. [PubMed]
3. Szuster RR. Methamphetamine in psychiatric emergencies. Hawaii Med J. 1990 Oct;49(10):389–391. PubMed. [PubMed]
4. Swanson SM, Sise CB, Sise MJ, Sack DI, Holbrook TL, Paci GM. The scourge of methamphetamine: impact on a level I trauma center. J Trauma. 2007 Sep;63(3):531–537. PubMed. [PubMed]
5. Tominaga GT, Garcia G, Dzierba A, Wong J. Toll of methamphetamine on the trauma system. Arch Surg. 2004 Aug;139(8):844–847. PubMed. [PubMed]
6. Cartier J, Farabee D, Prendergast ML. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J Interpers Violence. 2006 Apr;21(4):435–445. PubMed. [PubMed]
7. Cohen JB, Dickow A, Horner K, et al. Abuse and violence history of men and women in treatment for methamphetamine dependence. Am J Addict. 2003 Oct-Dec;12(5):377–385. PubMed. [PubMed]
8. McKetin R, McLaren J, Lubman DI, Hides L. Hostility among methamphetamine users experiencing psychotic symptoms. Am J Addict. 2008 May-Jun;17(3):235–240. PubMed. [PubMed]
9. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004 Mar-Apr;13(2):181–190. PubMed. [PubMed]
10. Gonzales R, Mooney L, Rawson RA. The methamphetamine problem in the United States. Annu Rev Public Health. 2010 Apr 21;31:385–398. PubMed. [PubMed]
11. Watanabe-Galloway S, Ryan S, Hansen K, Hullsiek B, Muli V, Malone AC. Effects of methamphetamine abuse beyond individual users. J Psychoactive Drugs. 2009 Sep;41(3):241–248. PubMed. [PubMed]
12. Boles SM, Miotto K. Substance abuse and violence - A review of the literature. Aggression and Violent Behavior. 2003 Mar-Apr;8(2):155–174.
13. Jaffe A, Pedersen WC, Fisher DG, et al. Drug use, personality and partner violence: A model of separate, additive, contributions in an active drug user sample. The Open Addiction Journal. 2009;2:39–47. PubMed. [PMC free article] [PubMed]
14. Stretesky PB. National Case-Control Study of Homicide Offending and Methamphetamine Use. Journal of Interpersonal Violence. 2009 Jun;24(6):911–924. PubMed. [PubMed]
15. Tyner EA, Fremouw WJ. The relation of methamphetamine use and violence: A critical review. Aggression and Violent Behavior. 2008 Aug-Sep;13(4):285–297.
16. Baskin-Sommers A, Sommers I. The co-occurrence of substance use and high-risk behaviors. Journal of Adolescent Health. 2006 May;38(5):609–611. PubMed. [PubMed]
17. Sommers I, Baskin D. Methamphetamine use and violence. Journal of Drug Issues. 2006;36(1):77–96. WIN.
18. Payer DE, Lieberman MD, Monterosso JR, Xu J, Fong T, London ED. Differences in cortical activity between methamphetamine-dependent and healthy individuals performing a facial affect matching task. Drug Alcohol Depend. 2008;93:93–102. PubMed. [PMC free article] [PubMed]
19. Henry JD, Mazur M, Rendell PG. Social-cognitive difficulties in former users of methamphetamine. Br J Clin Psychol. 2009 Sep;48(Pt 3):323–327. PubMed. [PubMed]
20. Sekine Y, Ouchi Y, Takei N, et al. Brain Serotonin Transporter Density and Aggression in Abstinent Methamphetamine Abusers. Arch Gen Psychiatry. 2006;63(1):90–100. PubMed. [PubMed]
21. Anderson CA, Bushman BJ. Human aggression. Annu Rev Psychol. 2002;53:27–51. PubMed. [PubMed]
22. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED. Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs. May;71(3):335–344. PubMed. [PubMed]
23. Scott JC, Woods SP, Matt GE, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007 Sep;17(3):275–297. PubMed. [PubMed]
24. Salo R, Nordahl TE, Possin K, et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Research. 2002;111(1):65–74. PubMed. [PubMed]
25. Salo R, Nordahl TE, Moore C, et al. A dissociation in attentional control: evidence from methamphetamine dependence. Biological Psychiatry. 2005;57(3):310–313. PubMed. [PubMed]
26. Monterosso JR, Aron AR, Cordova X, Xu J, London ED. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug and Alcohol Dependence. 2005;79(2):273–277. PubMed. [PubMed]
27. Salo R, Ursu S, Buonocore MH, Leamon MH, Carter C. Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study. Biol Psychiatry. 2009 Apr 15;65(8):706–709. PubMed. [PMC free article] [PubMed]
28. Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biological Psychiatry. 2003;53:65–74. PubMed. [PubMed]
29. Monterosso J, Domier C, Ainslie G, Xu J, Cordova X, London ED. Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a parametric delay-discounting task. Human Brain Mapping. 2006 [PubMed]
30. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl) 2006 Oct;188(2):162–170. [PubMed]
31. Goldstein RZ, Craig AD, Bechara A, et al. The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci. 2009 Sep;13(9):372–380. PubMed. [PMC free article] [PubMed]
32. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull. 2008 Mar;134(2):301–310. PubMed. [PubMed]
33. Verdejo-Garcia A, Perez-Garcia M. Substance abusers’ self-awareness of the neurobehavioral consequences of addiction. Psychiatry Res. 2008 Mar 15;158(2):172–180. PubMed. [PubMed]
34. Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation--a possible prelude to violence. Science. 2000 Jul 28;289(5479):591–594. PubMed. [PubMed]
35. Adolphs R. Is the human amygdala specialized for processing social information? Ann N Y Acad Sci. 2003 Apr;985:326–340. PubMed. [PubMed]
36. LeDoux J. The amygdala. Curr Biol. 2007 Oct 23;17(20):R868–874. PubMed. [PubMed]
37. Costafreda SG, Brammer MJ, David AS, Fu CH. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain Res Rev. 2008 Jun;58(1):57–70. PubMed. [PubMed]
38. Sergerie K, Chochol C, Armony JL. The role of the amygdala in emotional processing: a quantitative meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev. 2008;32(4):811–830. PubMed. [PubMed]
39. Adolphs R. Recognizing emotion from facial expressions: psychological and neurological mechanisms. Behav Cogn Neurosci Rev. 2002 Mar;1(1):21–62. PubMed. [PubMed]
40. Sprengelmeyer R, Rausch M, Eysel UT, Przuntek H. Neural structures associated with recognition of facial expressions of basic emotions. Proc Biol Sci. 1998 Oct 22;265(1409):1927–1931. PubMed. [PMC free article] [PubMed]
41. Hornak J, Rolls ET, Wade D. Face and voice expression identification in patients with emotional and behavioural changes following ventral frontal lobe damage. Neuropsychologia. 1996 Apr;34(4):247–261. PubMed. [PubMed]
42. Lange K, Williams LM, Young AW, et al. Task instructions modulate neural responses to fearful facial expressions. Biol Psychiatry. 2003 Feb 1;53(3):226–232. PubMed. [PubMed]
43. Posamentier MT, Abdi H. Processing faces and facial expressions. Neuropsychol Rev. 2003 Sep;13(3):113–143. PubMed. [PubMed]
44. Barbas H. Flow of information for emotions through temporal and orbitofrontal pathways. J Anat. 2007 Aug;211(2):237–249. PubMed. [PubMed]
45. Petrides M, Pandya DN. Efferent association pathways from the rostral prefrontal cortex in the macaque monkey. J Neurosci. 2007 Oct 24;27(43):11573–11586. PubMed. [PubMed]
46. Quirk GJ, Beer JS. Prefrontal involvement in the regulation of emotion: convergence of rat and human studies. Curr Opin Neurobiol. 2006 Dec;16(6):723–727. PubMed. [PubMed]
47. Woermann FG, van Elst LT, Koepp MJ, et al. Reduction of frontal neocortical grey matter associated with affective aggression in patients with temporal lobe epilepsy: an objective voxel by voxel analysis of automatically segmented MRI. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):162–169. PubMed. [PMC free article] [PubMed]
48. Raine A, Buchsbaum M, LaCasse L. Brain abnormalities in murderers indciated by positron emission tomography. Biological Psychiatry. 1997;42:495–508. PubMed. [PubMed]
49. Raine A, Meloy JR, Bihrle S, Stoddard J, LaCasse L, Buchsbaum MS. Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Behav Sci Law. 1998;16(3):319–332. Summer. PubMed. [PubMed]
50. Bufkin JL, Luttrell VR. Neuroimaging studies of aggressive and violent behavior: current findings and implications for criminology and criminal justice. Trauma Violence Abuse. 2005 Apr;6(2):176–191. PubMed. [PubMed]
51. van Elst LT, Woermann FG, Lemieux L, Thompson PJ, Trimble MR. Affective aggression in patients with temporal lobe epilepsy: a quantitative MRI study of the amygdala. Brain. 2000 Feb;123(Pt 2):234–243. PubMed. [PubMed]
52. Coccaro EF, McCloskey MS, Fitzgerald DA, Phan KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol Psychiatry. 2007 Jul 15;62(2):168–178. PubMed. [PubMed]
53. New AS, Hazlett EA, Buchsbaum MS, et al. Amygdala-prefrontal disconnection in borderline personality disorder. Neuropsychopharmacology. 2007 Jul;32(7):1629–1640. PubMed. [PubMed]
54. Pietrini P, Guazzelli M, Basso G, Jaffe K, Grafman J. Neural correlates of imaginal aggressive behavior assessed by positron emission tomography in healthy subjects. Am J Psychiatry. 2000 Nov;157(11):1772–1781. PubMed. [PubMed]
55. Lieberman MD, Eisenberger NI, Crockett MJ, Tom SM, Pfeifer JH, Way BM. Putting feelings into words: affect labeling disrupts amygdala activity in response to affective stimuli. Psychol Sci. 2007 May;18(5):421–428. PubMed. [PubMed]
56. Hariri AR, Bookheimer SY, Mazziotta JC. Modulating emotional responses: effects of a neocortical network on the limbic system. Neuroreport. 2000 Jan 17;11(1):43–48. PubMed. [PubMed]
57. Hariri AR, Mattay VS, Tessitore A, Fera F, Weinberger DR. Neocortical modulation of the amygdala response to fearful stimuli. Biological Psychiatry. 2003;53(6):494–501. PubMed. [PubMed]
58. Goldin PR, McRae K, Ramel W, Gross JJ. The neural bases of emotion regulation: reappraisal and suppression of negative emotion. Biol Psychiatry. 2008 Mar 15;63(6):577–586. PubMed. [PMC free article] [PubMed]
59. Phan KL, Fitzgerald DA, Nathan PJ, Moore GJ, Uhde TW, Tancer ME. Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study. Biol Psychiatry. 2005 Feb 1;57(3):210–219. PubMed. [PubMed]
60. Schaefer SM, Jackson DC, Davidson RJ, Aguirre GK, Kimberg DY, Thompson-Schill SL. Modulation of amygdalar activity by the conscious regulation of negative emotion. J Cogn Neurosci. 2002 Aug 15;14(6):913–921. PubMed. [PubMed]
61. Beauregard M, Levesque J, Bourgouin P. Neural correlates of conscious self-regulation of emotion. J Neurosci. 2001 Sep 15;21(18) PubMed. [PubMed]
62. Urry HL, van Reekum CM, Johnstone T, et al. Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults. J Neurosci. 2006 Apr 19;26(16):4415, 4425. PubMed. [PubMed]
63. Ochsner KN, Gross JJ. The cognitive control of emotion. Trends Cogn Sci. 2005;9(5):242–249. PubMed. [PubMed]
64. Driscoll D, Tranel D, Anderson SW. The effects of voluntary regulation of positive and negative emotion on psychophysiological responsiveness. Int J Psychophysiol. 2009 Apr;72(1):61–66. PubMed. [PMC free article] [PubMed]
65. Wager TD, Davidson ML, Hughes BL, Lindquist MA, Ochsner KN. Prefrontal-subcortical pathways mediating successful emotion regulation. Neuron. 2008 Sep 25;59(6):1037–1050. PubMed. [PMC free article] [PubMed]
66. Ochsner KN, Ray RD, Cooper JC, et al. For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotion. Neuroimage. 2004 Oct;23(2):483–499. PubMed. [PubMed]
67. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends in Cognitive Sciences. 2004;8(4):170–177. PubMed. [PubMed]
68. Thompson PM, Hayashi K, Simon SL, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004;24(26):6028–6036. PubMed. [PubMed]
69. Payer D, London ED. Methamphetamine and the brain: Findings from brain imaging studies. In: Roll JM, Rawson R, Ling W, Shoptaw S, editors. Methamphetamine Addiction: From Basic Science To Treatment. Guildford Press; New York: 2009.
70. Baicy K, London ED. Corticolimbic dysregulation and chronic methamphetamine abuse. Addiction. 2007 Apr;102(Suppl 1):5–15. PubMed. [PubMed]
71. Aron JL, Paulus MP. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction. 2007;102(Suppl 1):33–43. PubMed. [PubMed]
72. Hoffman WF, Schwartz DL, Huckans MS, et al. Cortical activation during delay discounting in abstinent methamphetamine dependent individuals. Psychopharmacology (Berl) 2008 Dec;201(2):183–193. [PMC free article] [PubMed]
73. Kim YT, Lee JJ, Song HJ, et al. Alterations in cortical activity of male methamphetamine abusers performing an empathy task: fMRI study. Hum Psychopharmacol. 2010 Jan;25(1):63–70. PubMed. [PubMed]
74. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. American Journal of Psychiatry. 2003;160:1699–1701. PubMed. [PubMed]
75. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004 Jan;61(1):73–84. PubMed. [PubMed]
76. Goldstein RZ, Volkow ND, Chang L, et al. The orbitofrontal cortex in methamphetamine addiction: involvement in fear. NeuroReport. 2002;13(17):2253–2257. PubMed. [PMC free article] [PubMed]
77. Li CS, Sinha R. Inhibitory control and emotional stress regulation: neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction. Neurosci Biobehav Rev. 2008;32(3):581–597. PubMed. [PMC free article] [PubMed]
78. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 2007 Apr;102(Suppl 1):16–32. PubMed. [PubMed]
79. Berkman ET, Lieberman MD. Using neuroscience to broaden emotion regulation: Theoretical and methodological considerations. Social and Personality Psychology Compass. 2009;3/4:475–403. [PMC free article] [PubMed]
80. Tabibnia G, Lieberman MD, Craske MG. The lasting effect of words on feelings: words may facilitate exposure effects to threatening images. Emotion. 2008 Jun;8(3):307–317. PubMed. [PubMed]
81. Esterling BA, L’Abate L, Murray EJ, Pennebaker JW. Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Clin Psychol Rev. 1999 Jan;19(1):79–96. PubMed. [PubMed]
82. First MB, Spitzer RL, Gibbon M, Williams JBW. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IP) American Psychiatric Press; Washington, D.C.: 1995.
83. Tottenham N, Tanaka JW, Leon AC, et al. The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. 2009 Aug 15;168(3):242–249. PubMed. [PMC free article] [PubMed]
84. Bushman BJ, Baumeister RF. Threatened egotism, narcissism, self-esteem, and direct and displaced aggression: does self-love or self-hate lead to violence? J Pers Soc Psychol. 1998 Jul;75(1):219–229. PubMed. [PubMed]
85. Anderson CA, Bushman BJ. External Validity of “Trivial” Experiments: The Case of Laboratory Aggression. Review of General Psychology. 1997;1(1):19–41.
86. Bernstein S, Richardson D, Hammock G. Convergent and discriminant validity of the Taylor and Buss measures of physical aggression. Aggressive Behavior. 1987;13:15–24.
87. Giancola PR, Zeichner A. An investigation of gender differences in alcohol-related aggression. J Stud Alcohol. 1995 Sep;56(5):573–579. PubMed. [PubMed]
88. Buss AH, Warren WL. Aggression Questionnaire: Manual. Western Psychological Services; Los Angeles, CA: 2000.
89. Spielberger CD. Manual for the State-Trait Anger Expression Inventory. Psychological Assessment Resources; Odessa, FL: 1988.
90. Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia Scale-II. Convergent, Discriminant, and Concurrent Validity. Journal of Psychosomatic Research. 1994;38:33–40. PubMed. [PubMed]
91. Zorick T, Nestor L, Miotto K, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. in press. [PubMed] [PMC free article] [PubMed]
92. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry. 1999 Feb;33(1):89–93. PubMed. [PubMed]
93. [Accessed June 16 2010];MacStim 3.0. WhiteAnt Occasional Publishing Web site. http://www.brainmapping.org/WhiteAnt/macstim.html/
94. Resonance Technology. Inc Web site http://www.mrivideo.com/
95. [Accessed June 16 2010];Wellcome Trust Centre for Neuroimaging. Web site http://www.fil.ion.ucl.ac.uk/spm/software/spm5/
96. Patenaude B. England University of Oxford; Oxford: 2007. Bayesian statistical models of shape and appearance for subcortical brain segmentation.
97. Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox. Neuroimage. 2002;16(2):1140–1141.
98. Friston KJ, Buechel C, Fink GR, Morris J, Rolls E, Dolan RJ. Psychophysiological and modulatory interactions in neuroimaging. Neuroimage. 1997;6:219–229. [PubMed]
99. Gitelman DR, Penny WD, Ashburner J, Friston KJ. Modeling regional and psychophysiologic interactions in fMRI: the importance of hemodynamic deconvolution. Neuroimage. 2003 May;19(1):200–207. PubMed. [PubMed]
100. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19(3):1233–1239. PubMed. [PubMed]
101. Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci. 2009 Dec;4(4):423–428. PubMed. [PMC free article] [PubMed]
102. Ashburner J, Friston KJ. Voxel-Based Morphometry -- The Methods. Neuroimage. 2000;11(6):805–821. PubMed. [PubMed]
103. Fusar-Poli P, Placentino A, Carletti F, et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci. 2009 Nov;34(6):418–432. PubMed. [PMC free article] [PubMed]
104. Haxby JV, Hoffman EA, Gobbini MI. Human neural systems for face recognition and social communication. Biol Psychiatry. 2002 Jan 1;51(1):59–67. PubMed. [PubMed]
105. Reker M, Ohrmann P, Rauch AV, et al. Individual differences in alexithymia and brain response to masked emotion faces. Cortex. May;46(5):658–667. PubMed. [PubMed]
106. Kano M, Fukudo S, Gyoba J, et al. Specific brain processing of facial expressions in people with alexithymia: an H2 15O-PET study. Brain. 2003 Jun;126(Pt 6):1474–1484. PubMed. [PubMed]
107. Bermond B, Vorst HC, Moormann PP. Cognitive neuropsychology of alexithymia: implications for personality typology. Cogn Neuropsychiatry. 2006 May;11(3):332–360. PubMed. [PubMed]
108. Lapworth K, Dawe S, Davis P, Kavanagh D, Young R, Saunders J. Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict Behav. 2009 Apr;34(4):380–385. PubMed. [PubMed]
109. Shamay-Tsoory SG, Tomer R, Berger BD, Goldsher D, Aharon-Peretz J. Impaired “affective theory of mind” is associated with right ventromedial prefrontal damage. Cogn Behav Neurol. 2005 Mar;18(1):55–67. PubMed. [PubMed]
110. Blair RJ, Cipolotti L. Impaired social response reversal. A case of ‘acquired sociopathy. Brain. 2000 Jun;123(Pt 6):1122–1141. PubMed. [PubMed]
111. Blair RJ. The roles of orbital frontal cortex in the modulation of antisocial behavior. Brain Cogn. 2004 Jun;55(1):198–208. PubMed. [PubMed]